Advertisement

Identifying post-menopausal women at elevated risk for epithelial ovarian cancer

Published:September 03, 2015DOI:https://doi.org/10.1016/j.ygyno.2015.08.024

      Highlights

      • Risk for ovarian cancer was predicted using data from the Women's Health Initiative.
      • Predictors include serum markers as well as epidemiologic risk factors.
      • At-risk post-menopausal women were identified, independent of deleterious mutations.
      • 8% of women were classified as elevated risk, and 31% of cancers were identified.
      • A125 and HE4 contributed significantly to risk prediction.

      ABSTRACT

      Objective

      We developed and validated a hybrid risk classifier combining serum markers and epidemiologic risk factors to identify post-menopausal women at elevated risk for invasive fallopian tube, primary peritoneal, and ovarian epithelial carcinoma.

      Methods

      To select epidemiologic risk factors for use in the classifier, Cox proportional hazards analyses were conducted using 74,786 Women's Health Initiative (WHI) Observational Study (OS) participants. To construct a combination classifier, 210 WHI OS cases and 536 matched controls with serum marker measurements were analyzed; validation employed 143 cases and 725 matched controls from the WHI Clinical Trial (CT) with similar data.

      Results

      Analyses identified a combination risk classifier composed of two elevated-risk groups: 1) women with CA125 or HE4 exceeding a 98% specificity threshold; and 2) women with intact fallopian tubes, prior use of menopausal hormone therapy for at least two years, and either a first degree relative with breast or ovarian cancer or a personal history of breast cancer. In the WHI OS population, it classified 13% of women as elevated risk, identifying 30% of ovarian cancers diagnosed up to 7.8 years post-enrollment (Hazard Ratio [HR] = 2.6, p < 0.001). In the WHI CT validation population, it classified 8% of women as elevated risk, identifying 31% of cancers diagnosed within 7 years of enrollment (HR = 4.6, p < 0.001).

      Conclusion

      CA125 and HE4 contributed significantly to a risk prediction classifier combining serum markers with epidemiologic risk factors. The hybrid risk classifier may be useful to identify post-menopausal women who would benefit from timely surgical intervention to prevent epithelial ovarian cancer.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Gynecologic Oncology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Andersen M.R.
        • Goff B.A.
        • Lowe K.A.
        • Scholler N.
        • Bergan L.
        • Drescher C.W.
        • et al.
        Use of a symptom index, CA125, and HE4 to predict ovarian cancer.
        Gynecol. Oncol. 2010; 116 (Epub 2009/12/01): 378-383
        • Ramus S.J.
        • Gayther S.A.
        The contribution of BRCA1 and BRCA2 to ovarian cancer.
        Mol. Oncol. 2009; 3 (Epub 2009/04/23): 138-150
        • Antoniou A.
        • Pharoah P.
        • Narod S.
        • et al.
        Average risk of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies.
        Am. J. Hum. Genet. 2003; 72: 1117-1130
        • Rebbeck T.R.
        • Kauff N.D.
        • Domchek S.M.
        Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers.
        J. Natl. Cancer Inst. 2009; 101 (Epub 2009/01/15): 80-87
        • Nelson H.D.
        • Fu R.
        • Goddard K.
        • Mitchell J.P.
        • Okinaka-Hu L.
        • Pappas M.
        • et al.
        Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer: Systematic Review to Update the US Preventive Services Task Force Recommendation. Rockville (MD).
        2013
        • Parker W.H.
        • Shoupe D.
        • Broder M.S.
        • Liu Z.
        • Farquhar C.
        • Berek J.S.
        Elective oophorectomy in the gynecological patient: when is it desirable?.
        Curr. Opin. Obstet. Gynecol. 2007; 19 (Epub 2007/07/13): 350-354
        • McAlpine J.N.
        • Hanley G.E.
        • Woo M.M.
        • Tone A.A.
        • Rozenberg N.
        • Swenerton K.D.
        • et al.
        Opportunistic salpingectomy: uptake, risks and complications of a regional initiative for ovarian cancer prevention.
        Am. J. Obstet Gynecol. 2014; (Epub 2014/01/15)
        • Folkins A.K.
        • Jarboe E.A.
        • Roh M.H.
        • Crum C.P.
        Precursors to pelvic serous carcinoma and their clinical implications.
        Gynecol. Oncol. 2009; 113 (Epub 2009/02/25): 391-396
        • Dietl J.
        • Wischhusen J.
        • Hausler S.F.
        The post-reproductive fallopian tube: better removed?.
        Hum. Reprod. 2011; 26 (Epub 2011/08/19): 2918-2924
        • Morelli M.
        • Venturella R.
        • Mocciaro R.
        • Di Cello A.
        • Rania E.
        • Lico D.
        • et al.
        Prophylactic salpingectomy in premenopausal low-risk women for ovarian cancer: Primum non nocere.
        Gynecol. Oncol. 2013; (pii: S0090-8258(13):00178–9, Epub 2013/04/06)
        • Gilks C.B.
        • Miller D.
        Opportunistic salpingectomy for women at low risk for development of ovarian carcinoma: the time has come.
        Gynecol. Oncol. 2013; 129 (Epub 2013/05/15): 443-444
        • Berek J.S.
        • Chalas E.
        • Edelson M.
        • Moore D.H.
        • Burke W.M.
        • Cliby W.A.
        • et al.
        Prophylactic and risk-reducing bilateral salpingo-oophorectomy: recommendations based on risk of ovarian cancer.
        Obstet. Gynecol. 2010; 116 (Epub 2010/08/25): 733-743
        • Kauff N.D.
        • Mitra N.
        • Robson M.E.
        • Hurley K.E.
        • Chuai S.
        • Goldfrank D.
        • et al.
        Risk of ovarian cancer in BRCA1 and BRCA2 mutation-negative hereditary breast cancer families.
        J. Natl. Cancer Inst. 2005; 97: 1382-1384
        • Metcalfe K.A.
        • Finch A.
        • Poll A.
        • Horsman D.
        • Kim-Sing C.
        • Scott J.
        • et al.
        Breast cancer risks in women with a family history of breast or ovarian cancer who have tested negative for a BRCA1 or BRCA2 mutation.
        Br. J. Cancer. 2009; 100 (Epub 2008/12/18): 421-425
        • Anderson G.L.
        • McIntosh M.W.
        • Wu L.
        • Barnett M.
        • Goodman G.
        • Thorpe J.D.
        • et al.
        Assessing lead time of selected ovarian cancer biomarkers: a nested case–control study.
        J. Natl. Cancer Inst. 2010; 102: 26-38
        • Hermsen B.B.J.
        • von Mensdorff-Pouilly S.
        • Berkhof J.
        • van Diest P.J.
        • Gille J.J.P.
        • Menko F.H.
        • et al.
        Serum CA-125 in relation to adnexal dysplasia and cancer in women at hereditary high risk of ovarian cancer.
        J. Clin. Oncol. 2007; 25: 1383-1389
        • Karlsen M.A.
        • Sandhu N.
        • Hogdall C.
        • Christensen I.J.
        • Nedergaard L.
        • Lundvall L.
        • et al.
        Evaluation of HE4, CA125, risk of ovarian malignancy algorithm (ROMA) and risk of malignancy index (RMI) as diagnostic tools of epithelial ovarian cancer in patients with a pelvic mass.
        Gynecol. Oncol. 2012; 127 (Epub 2012/07/28): 379-383
        • Moore R.G.
        • Miller M.C.
        • Steinhoff M.M.
        • Skates S.J.
        • Lu K.H.
        • Lambert-Messerlian G.
        • et al.
        Serum HE4 levels are less frequently elevated than CA125 in women with benign gynecologic disorders.
        Am. J. Obstet. Gynecol. 2012; 206 (e1-8, Epub 2012/01/31): 351
        • Buys S.S.
        • Partridge E.
        • Black A.
        • Johnson C.J.
        • Lamerato L.
        • Isaacs C.
        • et al.
        Effect of screening on ovarian cancer mortality: the prostate, lung, colorectal and ovarian (PLCO) cancer screening randomized controlled trial.
        JAMA. 2011; 305: 2295-2303
        • Cramer D.W.
        • Bast Jr., R.C.
        • Berg C.D.
        • Diamandis E.P.
        • Godwin A.K.
        • Hartge P.
        • et al.
        Ovarian cancer biomarker performance in prostate, lung, colorectal, and ovarian cancer screening trial specimens.
        Cancer Prev. Res. (Phila.). 2011; 4: 365-374
        • Zhu C.S.
        • Pinsky P.F.
        • Cramer D.W.
        • Ransohoff D.F.
        • Hartge P.
        • Pfeiffer R.M.
        • et al.
        For the PLCO Project Team. A framework for evaluating biomarkers for early detection: validation of biomarker panels for ovarian cancer.
        Cancer Prev. Res. (Phila.). 2011; 4: 375-383
        • Urban N.
        • Thorpe J.D.
        • Bergan L.A.
        • Forrest R.M.
        • Kampani A.V.
        • Scholler N.
        • et al.
        Potential role of HE4 in multimodal screening for epithelial ovarian cancer.
        J. Natl. Cancer Inst. 2011; 103 (Epub 2011/09/16): 1630-1634
        • Vitonis A.F.
        • Titus-Ernstoff L.
        • Cramer D.W.
        Assessing ovarian cancer risk when considering elective oophorectomy at the time of hysterectomy.
        Obstet. Gynecol. 2011; 117 (Epub 2011/04/08): 1042-1050
        • Morch L.S.
        • Lokkegaard E.
        • Andreasen A.H.
        • Kjaer S.K.
        • Lidegaard O.
        Hormone therapy and different ovarian cancers: a national cohort study.
        Am. J. Epidemiol. 2012; 175 (Epub 2012/04/21): 1234-1242
        • Koskela-Niska V.
        • Lyytinen H.
        • Riska A.
        • Pukkala E.
        • Ylikorkala O.
        Ovarian cancer risk in postmenopausal women using estradiol-progestin therapy — a nationwide study.
        Climacteric. 2013; 16 (Epub 2012/05/30): 48-53
        • Koskela-Niska V.
        • Pukkala E.
        • Lyytinen H.
        • Ylikorkala O.
        • Dyba T.
        Effect of various forms of postmenopausal hormone therapy on the risk of ovarian cancer—a population-based case control study from Finland.
        Int. J. Cancer. 2013; 133 (Epub 2013/03/26): 1680-1688
        • Anderson G.L.
        Implementation of the Women's Health Initiative Study Design.
        Ann. Epidemiol. 2003; 13: S5-17
        • Curb J.D.
        • McTiernan A.
        • Heckbert S.R.
        • Kooperberg C.
        • Stanford J.
        • Nevitt M.
        • et al.
        Outcomes ascertainment and adjudication methods in the Women's Health Initiative.
        Ann. Epidemiol. 2003; 13 (Epub 2003/10/25): S122-S128
        • Morris C.R.
        • Liu L.
        • Rodriguez A.O.
        • Cress R.D.
        • Snipes K.
        Epidemiologic features of borderline ovarian tumors in California: a population-based study.
        Cancer Causes Control. 2013; 24 (Epub 2013/01/15): 665-674
        • Kurman R.J.
        • Trimble C.L.
        The behavior of serous tumors of low malignant potential: are they ever malignant?.
        Int. J. Gynecol. Pathol. 1993; 12 (Epub 1993/04/01): 120-127
        • Leake J.F.
        • Currie J.L.
        • Rosenshein N.B.
        • Woodruff J.D.
        Long-term follow-up of serous ovarian tumors of low malignant potential.
        Gynecol. Oncol. 1992; 47 (Epub 1992/11/01): 150-158
        • Sherman M.E.
        • Mink P.J.
        • Curtis R.
        • Cote T.R.
        • Brooks S.
        • Hartge P.
        • et al.
        Survival among women with borderline ovarian tumors and ovarian carcinoma: a population-based analysis.
        Cancer. 2004; 100 (Epub 2004/02/26): 1045-1052
        • McIntosh M.
        • Urban N.
        A parametric empirical Bayes method for cancer screening using longitudinal observations of a biomarker.
        Biostatistics. 2003; 4: 27-40
        • McIntosh M.
        • Urban N.
        • Karlan B.
        Generating longitudinal screening algorithms using novel biomarkers for disease.
        Cancer Epidemiol. Biomark. Prev. 2002; 11: 159-166
        • Urban N.
        • Thorpe J.D.
        • Karlan B.Y.
        • McIntosh M.W.
        • Palomares M.R.
        • Daly M.B.
        • et al.
        Interpretation of single and serial measures of HE4 and CA125 in asymptomatic women at high risk for ovarian cancer.
        Cancer Epidemiol. Biomark. Prev. 2012; 21 (Epub 2012/09/07): 2087-2094
        • Schonfeld S.J.
        • Berrington de Gonzalez A.
        • Visvanathan K.
        • Pfeiffer R.M.
        • Anderson W.F.
        Declining second primary ovarian cancer after first primary breast cancer.
        J. Clin. Oncol. 2013; 31 (Epub 2013/01/04): 738-743
        • Obermair A.
        • Youlden D.R.
        • Baade P.D.
        • Janda M.
        The impact of risk-reducing hysterectomy and bilateral salpingo-oophorectomy on survival in patients with a history of breast cancer—a population-based data linkage study.
        Int. J. Cancer. 2014; 134 (Epub 2013/10/16): 2211-2222
        • SEER Cancer Statistics Review
        1975–2011 National Cancer Institute. Bethesda, MD.
        (cited 2015 4/7/15)
        • Piver M.S.
        Prophylactic oophorectomy: reducing the U.S. Death rate from epithelial ovarian cancer. A continuing debate.
        Oncologist. 1996; 1 (Epub 1996/01/01): 326-330
        • Rosenthal A.N.
        • Fraser L.
        • Manchanda R.
        • Badman P.
        • Philpott S.
        • Mozersky J.
        • et al.
        Results of annual screening in phase I of the United Kingdom familial ovarian cancer screening study highlight the need for strict adherence to screening schedule.
        J. Clin. Oncol. 2013; 31 (Epub 2012/12/06): 49-57
        • Pearce C.L.
        • Stram D.O.
        • Ness R.B.
        • Stram D.A.
        • Roman L.D.
        • Templeman C.
        • et al.
        Population distribution of lifetime risk of ovarian cancer in the United States.
        Cancer Epidemiol. Biomark. Prev. 2015; 24 (Epub 2015/01/28): 671-676
        • Powell C.B.
        • Swisher E.M.
        • Cass I.
        • McLennan J.
        • Norquist B.
        • Garcia R.L.
        • et al.
        Long term follow up of BRCA1 and BRCA2 mutation carriers with unsuspected neoplasia identified at risk reducing salpingo-oophorectomy.
        Gynecol. Oncol. 2013; 129 (Epub 2013/02/09): 364-371